(00:32)
 Can you please tell our listeners a little about yourself and your background?

(01:00)
 Mayo Clinic Laboratories already offers one test for Alzheimer's disease, right?

(01:32) 
 Could you tell our listeners about the new FDA-approved test that Mayo Clinic Laboratories will launch soon?

(02:43)
 The test results will report the ratio of the amyloid isoforms, not the individual test components, right?

(03:26)
 Does the new test require a certain tube?

(04:15)
 Can you provide a little more detail on the commercially available tube that will be required?

(04:36)
 Which patient population would benefit most from this test?

(05:30)
 Can you compare and contrast the existing Alzheimer's disease test and the new amyloid ratio evaluation?

(08:58)
 Is Mayo Clinic's ADEVL the only test that measures the tau component?

(09:51)
 When would one of these tests be more appropriate than the other?

(10:52)
 Can you help our listeners understand what a "laboratory developed" test means?

(11:43)
 From a physician's standpoint, how might this new test improve patient care?

(00:32):

Before we jump in, would each of you share a little bit about your background and yourselves?
 
(01:18):

Dr. Marcou. could you provide us with an overview of what the WESDX test is?

 
(01:50):

Marissa, would you help explain why this test is important?

(03:10):

In your experience who would benefit from WESDX,

(05:12):

How does a provider order A WES DX and secondarily what type of samples are accepted?

(06:24):

What types of variants are detected by the test?

(07:47):

There are a lot of exome tests available. What are some other unique features that set WESDX apart?

(09:52):

Last question, could you summarize the benefits of doing WESDX at Mayo?